8. American Diabetes Association. Standards for medical care in 35. Nauck MA, Heimesaat MM, Orskov C, et al.
Preserved
diabe- tes—2007. Diabetes Care 2007;30(Suppl 1):S4–S41.
9. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of
diabetes and impaired fasting glucose in adults in the U.S.
population. Diabetes Care 2006;29:1263–1268.
10. American Diabetes Association. Type 2 diabetes in children
BAGIAN 8
and adolescents. Diabetes Care 2000;23:381–389.
11. Kahn SE, Porte D Jr. The pathophysiology of type II (non-
insulin dependent) diabetes mellitus: Implications for
treatment. In: Porte D Jr, Sherwin RS, eds. Ellenberg &
Rifkin’s Diabetes Mellitus, 5th ed. Stamford, CT: Appleton &
Lange, 1997:487–512.
12. American Diabetes Association. Gestational diabetes
mellitus. Diabe- tes Care 2004;27(Suppl 1):S88–S90.
13. Report of the expert committee on the diagnosis and
classification of diabetes mellitus. Diabetes Care
1997;20:1183–1197.
Gangguan Endokrinologi
14. van Tilburg J, van Haeften TW, Pearson P, Wijimenga C.
Defining the genetic contribution of type 2 diabetes mellitus. J
Med Genet 2001;38:569– 578.
15. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison
of fasting and 2-hour glucose and HbAlc levels for diagnosing
diabetes: Diagnostic criteria and performance revisited.
Diabetes Care 1997;20:785–791.
16. McCance DR, Hanson RL, Charles MA, et al. Comparison
of tests for glycated haemoglobin and fasting and two hour
plasma glucose concen- trations as diagnostic methods for
diabetes. BMJ 1994;308:1323–1328.
17. Janeway CA. Immunology relevant to diabetes. In: Porte D
Jr, Sherwin RS, eds. Ellenberg & Rifkin’s Diabetes Mellitus,
5th ed. Stamford, CT: Appleton & Lange, 1997:287–300.
18. Edelman SV, Weyer C. Unresolved challenges with insulin
therapy in type 1 and type 2 diabetes: Potential benefit of
replacing amylin, a second -cell hormone. Diabetes
Technol Ther 2002;4:175–189.
19. Cherrington AD. Banting Lecture 1997: Control of glucose
uptake and release by the liver in vivo. Diabetes
1999;48:1198–1214.
20. McGarry JD. Banting Lecture 2001: Dysregulation of fatty
acid metab- olism in the etiology of type 2 diabetes. Diabetes
2002;51:7–18.
21. Nogid A, Pham DQ. Adjunctive therapy with pramlintide in
patients with type 1 or type 2 diabetes mellitus.
Pharmacotherapy 2006;26:1626–1640.
22. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus:
Metabolic and molecular implications for identifying diabetes
genes. Diabetes 1997;5:117– 269.
23. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal
gluconeogenesis. Its importance in human glucose
homeostasis. Diabetes Care 2001;24:382– 391.
24. Ekberg K, Landau BR, Wajngot A, et al. Contributions by
kidney and liver to glucose production in the postabsorptive
state and after 60 h of fasting. Diabetes 1999;48:292–298.
25. Unger RH, Orci L. Glucagon and the cell: Physiology and
patho- physiology (first two parts). N Engl J Med
1981;304:1518–1524.
26. Mandarino L, Bonadonna R, McGuinness O, Wasserman D.
Regula- tion of muscle glucose uptake in vivo. In: Jefferson
LS, Cherrington AD, eds. Handbook of Physiology, Section
7, the Endocrine System, vol. II, the Endocrine Pancreas
and Regulation of Metabolism. Oxford: Oxford University
Press, 2001:803–848.
27. Santomauro A, Boden G, Silva M, et al. Overnight lowering of
free fatty acids with acipimox improves insulin resistance and
glucose tolerance in obese diabetic and non-diabetic subjects.
Diabetes 1999;48:1836–1841.
28. Bergman RN. Non-esterified fatty acids and the liver: Why is
insulin secreted into the portal vein? Diabetologia
2000;43:946–952.
29. Boden G. Role of fatty acids in the pathogenesis of insulin
resistance and NIDDM. Diabetes 1997;46:3–10.
30. DeFronzo RA, Ferrannini E, Simonson DC. Fasting
hyperglycemia in non-insulin-dependent diabetes mellitus:
Contributions of excessive hepatic glucose production and
impaired tissue glucose uptake. Metabo- lism 1989;38:387–
395.
31. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced
incretin effect in type 2 (non-insulin-dependent) diabetes.
Diabetologia 1986;291:46–52.
32. Jolst JJ, Gromada J. Role of incretin hormones in the
regulation of insulin secretion in diabetic and nondiabetic
humans. Am J Physiol Endocrinol Metab 2004;287:E199-
E206.
33. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2
diabetes mellitus. Diabetologia 2004;47:357–366.
34. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric
inhibitory polypeptide: The neglected incretin revisited. Regul
Pept 2002;107:1–13.
incretin activity of glucagon-like peptide-1 [7–36amide] but
not of synthetic human gastric inhibitory polypeptide in
patients with type 2 diabetes mellitus. J Clin Invest
1993;91:301–307.
36. Deacon CF, Nauck MA, Tolf-Nielsen M, et al. Both
subcutaneously and intravenously administered glucagon-
like peptide I are rapidly degraded from the NH2-terminus in
type II diabetic patients and in healthy subjects. Diabetes
1995;44:1126–1131.
37. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM.
Studies of pancreatic cell function in normal and diabetic
subjects. J Clin Invest 1970;49:837–848.
38. Kelley DE, Mandarino LJ. Fuel selection in human skeletal
muscle in insulin resistance. A reexamination. Diabetes
2000;49:677–683.
39. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase
in plasma free fatty acids impairs insulin secretion in
nondiabetic subjects genetically predisposed to develop type 2
diabetes. Diabetes 2003;52:2461–2474.
40. Carpentier A, Mittelman SD, Bergman RN, et al. Prolonged
elevation of plasma free fatty acids impairs pancreatic beta-
cell function in obese nondiabetic humans but not in
individuals with type 2 diabetes. Diabetes 2000;49:399–408.
41. Goodpaster BH, Thaete FL, Kelley BE. Thigh adipose tissue
distribu- tion is associated with insulin resistance in obesity
and in type 2 diabetes mellitus. Am J Clin Nutr 2000;71:885–
892.
42. Greco AV, Mingrone G, Giancaterini A, et al. Insulin
resistance in morbid obesity. Reversal with intramyocellular
fat depletion. Diabetes 2002;51:144–151.
43. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and
insulin action on free fatty acids and glucose metabolism rather
than insulin absorption are associated with insulin requirements
during insulin ther- apy in type 2 diabetic patients. Diabetes
2000;49:749–758.
44. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of
pioglitazone on abdominal fat distribution and insulin
sensitivity in type 2 diabetic patients. J Clin Endocrinol
Metab 2002;87:2784–2791.
45. DeFronzo RA. Pathogenesis of type 2 diabetes: Metabolic
and molecu- lar implications for identifying diabetes genes.
ADA 1997;4:177–269.
46. Ferrannini E, Natali A, Bell P, et al. On behalf of the
European Group for the Study of Insulin Resistance (EGIR).
Insulin resistance and hypersecretion in obesity. J Clin Invest
1997;100:1166–1173.
47. Montague CT, O’Rahilly S. The perils of portliness: Causes
and consequences of visceral adiposity. Diabetes
2000;49:883–888.
48. Kelley DE, Williams KV, Price JC, et al. Plasma fatty acids,
adiposity and variance of skeletal muscle insulin resistance in
type 2 diabetes mellitus. J Clin Endocrinol Metab
2001;86:5412–5419.
49. Banerji MA, Lebowitz J, Chaiken RL. Relationship of visceral
adipose tissue and glucose disposal is independent of sex in
black NIDDM subjects. Am J Physiol 1997;273:E425–E432.
50. Kelley DE. The impact of obesity, regional adiposity and
ectopic fat on the pathophysiology of type 2 diabetes.
Council on Obesity Diabetes Education 2003;12–20.
51. Weyer C, Funahashi T, Tanaka S, et al.
Hypoadiponectinemia in obesity and type 2 diabetes:
Close association with insulin resistance and
hyperinsulinemia. J Clin Endocrinol Metab 2000;86:1930–
1935.
52. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an
adipose- specific protein, adiponectin, in obesity. Biochem
Biophys Res Com- mun 1999;257:79–83.
53. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted
protein Acrp30 enhances hepatic insulin action. Nat Med
2001;7:947–953.
54. Yamauchi T, Kamon J, Waki H, et al. The fat-derived
hormone adi- ponectin reverses insulin resistance
associated with both lipoatrophy and obesity. Nat Med
2001;7:941–946.
55. Reaven GM. Role of insulin resistance in human disease.
Diabetes 1988;37:1595–1607.
56. International Diabetes Federation: The IDF consensus
worldwide defi- nition of the metabolic syndrome. 2007,
http://www.idf.org/webdata/ docs/MetS_def_update2006.pdf.
57. Ford ES. Prevalence of the metabolic syndrome defined by
the Inter- national Diabetes Federation among adults in the
U.S. Diabetes Care 2005;28:2745–2749.
58. Adams RJ, Appleton S, Wilson DH, et al. Population
comparison of two clinical approaches to the metabolic
syndrome: Implications of the new International Diabetes
Federation consensus definition. Diabetes Care
2005;28:2777–2779.
59. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention
and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med 2003;348:383–393.
60. Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. N Engl J Med
1993;329:977–986.
61. UK Prospective Diabetes Study Group. Intensive blood-
glucose con- trol with sulphonylureas or insulin compared
with conventional treat- ment and risk of complications in
patients with type 2 diabetes (UKPDS 33). Lancet
1998;352:837–853.
62. American Diabetes Association. Self-monitoring of blood
glucose. Diabetes Care 1994;17:81–86.
63. Welschen LMC, Bloemendal E, Nijpels G, et al. Self-
monitoring of glucose in patients with type 2 diabetes who
are not using insulin. Diabetes Care 2005;28:1510–1517.
64. American Diabetes Association. Nutrition
recommendations and interventions for diabetes. Diabetes
Care 2007;30(Suppl 1):S48–S65.
65. American Diabetes Association. Diabetes mellitus and
exercise. Diabe- tes Care 2004;27(Suppl 1):S58–S62.
66. Alberti KGMM, Zimmet P, DeFronzo RA, Keen H, eds.
International Textbook of Diabetes Mellitus, 2nd ed., vol. 1. New
York: Wiley, 1997:469– 610.
67. Insulin human (rDNA origin) inhalation Powder (Exubera)
[package insert]. New York: Pfizer Labs, Pfizer Inc., 2006.
68. Dewitt DE, Dugdale DC. Using new insulin strategies in the
outpatient treatment of diabetes: Clinical applications. JAMA
2003;289:2265–2269.
69. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1
and type 2 diabetes mellitus: scientific review. JAMA
2003;289:2254–2264.
70. Gerich JE. Novel insulins: Expanding options in diabetes
management. Am J Med 2002;113:308–316.
71. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics
and pharmacodynamics of subcutaneous injection of long-
acting human insulin analog glargine, NPH insulin, and
ultralente human insulin and continuous subcutaneous
infusion of insulin lispro. Diabetes 2000;49:2142–2148.
72. Malmberg K, for the DIGAMI Study Group. Prospective
randomised study of intensive insulin treatment on long term
survival after acute myocardial infarction in patients with diabetes
mellitus. BMJ 1997;314:1512–1515.
73. Kendall DM, Kim D, Poon T, et al. Improvements in
cardiovascular risk factors accompanied sustained effects
on glycemia and weight reduction in patient with type 2
diabetes treated with exenatide for 82 weeks. Diabetes
2005;54(Suppl 1):A4–5.
74. Schor S. The University Group Diabetes Program. A
statistician looks at the mortality results. JAMA
1971;217:1673–1675.
75. Kilo C, Miller L, Williamson J. The crux of the UGDP. Spurious
results and biologically inappropriate data analysis. Diabetologia
1980;18:179– 185.
76. Brady PA, Jovanovic A. The sulfonylurea controversy: Much
ado about nothing or cause for concern? J Am Coll Cardiol
2003;42:1022–1025.
77. Klamann A, Sarfert P, Lanhardt V, et al. Myocardial infarction in
diabetic vs. non-diabetic subjects: Survival and infarct size
following therapy with sulfonylureas (glibenclamide). Eur Heart J
2000;21:220–229.
78. Riddle MC. Sulfonylureas differ in effects on ischemic
preconditioning— Is it time to retire glyburide? J Clin Endocrinol
Metab 2003;88:528–530.
79. Gerich JE. Oral hypoglycemic agents. N Engl J Med
1989;321:1231– 1245.
80. Triplitt C. Drug interactions of medications commonly used in
diabe- tes. Diabetes Spectr 2006;19:202–211.
81. Wolffenbuttel BH, Landgraf R, for the Dutch and German
repaglinide study group. A 1-year multicenter randomized
double-blind compari- son of repaglinide and glyburide for
the treatment of type 2 diabetes. Diabetes Care
1999;22:463–467.
82. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone
and in combination with metformin improves glycemic control by
reducing mealtime glucose levels in type 2 diabetes. Diabetes
Care 2000;23:1660– 1665.
83. UK Prospective Diabetes Study (UKPDS) Group. Effect of
intensive blood-glucose control with metformin on
complications in overweight patients with type 2 diabetes
(UKPDS 34). Lancet 1998;352:854–865.
84. Dawson D, Conlon C. Case study: Metformin associated
lactic acido- sis: Could orlistat be relevant? Diabetes Care
2003;26:2471–2472.
85. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary
preven- tion of vascular events in patients with type 2
diabetes in the PROactive study prospective pioglitazone
BAB 77
clinical trial in macrovascular events: a randomized
controlled trial. Lancet 2005;366:1279–1289.
86. Nissen SE, Wolski K. The effect of rosiglitazone on the risk of
myocardial infarction and death from cardiovascular causes.
N Engl J Med 2007;356:1–15.
87. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function
in type 2 diabetic patients during clinical trials: Evidence that
rosiglitazone does not cause hepatic dysfunction. Diabetes
Care 2002;25:815–821.
88. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use,
Diabetes Mellitus
fluid retention, and congestive heart failure. A consensus
statement from the American Heart Association and the
American Diabetes Associa- tion. Diabetes Care
2004;27:256–263.
89. Mooradian AD, Thurman JE. Drug therapy of postprandial
hypergly- cemia. Drugs 1999;57:19–29.
90. Campbell LK, Baker DE, Campbell RK. Miglitol: Assessment
of its role in the treatment of patients with diabetes mellitus.
Ann Pharmacother 2000;34:1291–1301.
91. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for
prevention of type
2 diabetes mellitus: The STOP-NIDDM randomized trial.
Lancet 2002;359:2072–2077.
92. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment
and the risk of cardiovascular disease and hypertension in
patients with impaired glucose tolerance: The STOP-NIDDM
trial. JAMA 2003;290:486–494.
93. Lettieri JT, Dain B. Effects of beano on the tolerability and
pharmaco- dynamics of acarbose. Clin Ther 1998;20:497–
504.
94. EDIC writing group. Sustained effect of intensive treatment
of type 1 diabetes mellitus on development and progression
of diabetic nephropathy: The Epidemiology of Diabetes
Interventions and Com- plications of Study. JAMA
2003;290:2159–2167.
95. DCCT/EDIC Study Research Group. Intensive diabetes
treatment and cardiovascular disease in patients with type 1
diabetes. N Engl J Med 2005;353:2643–2653.
96. Stratton IM, Adler AI, Neil HA. Association of glycaemia with
mac- rovascular and microvascular complications of type 2
diabetes (UKPDS 35): Prospective observational study. BMJ
2000;321:405–412.
97. Adler AI, Stratton IM, Neil HA. Association of systolic blood
pressure with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 36): Prospective
observational study. BMJ 2000;321:412–419.
98. UK Prospective Diabetes Study Group. Efficacy of atenolol
and capto- pril in reducing risk of macrovascular and
microvascular complica- tions in type 2 diabetes: UKPDS 39.
BMJ 1998;317:713–720.
99. Strowig S, Raskin P. Intensive management of insulin-
dependent diabetes mellitus. In: Porte D Jr., Sherwin RS, eds.
Ellenberg & Rifkin’s Diabetes Mellitus, 5th ed. Stamford, CT:
Appleton & Lange, 1997:709–733.
100. Fanelli CG, Pampanelli S, Porcellati F, et al. Administration
of neutral protamine Hagedorn insulin at bedtime versus
with dinner in type 1 diabetes mellitus to avoid nocturnal
hypoglycemia and improve control. A randomized, controlled
trial. Ann Intern Med 2002;136:504–514.
101. DeVries JH, Snoek FJ, Kostense PJ, et al. on behalf of the
Dutch Insulin Pump Study Group. A randomized trial of
continuous subcutaneous insulin infusion and intensive
injection therapy in type 1 diabetes for patients with long-
standing poor glycemic control. Diabetes Care
2002;25:2074–2080.
102. Pickup J, Mattock M, Kerry S. Glycaemic control with
continuous subcutaneous insulin infusion compared with
intensive insulin injec- tions in patients with type 1 diabetes:
Meta-analysis of randomised controlled trials. BMJ
2002;324:705.
103. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin
infusion: A comprehensive review of insulin pump therapy.
Arch Intern Med 2001;161:2293–2300.
104. Schade DS, Valentine V. To pump or not to pump. Diabetes
Care 2002;25:2100–2102.
105. Cryer PE. Hypoglycemia is the limiting factor in the
management of diabetes. Diabetes Metab Res Rev
1999;15:42–46.
106. de Galan BE, Tack CJ, Lenders JW, et al. Theophylline
improves hypoglycemia unawareness in type 1 diabetes.
Diabetes 2002;51:790– 796.
107. Rosenbloom AL, Schatz DA, Krischer JP, et al. Therapeutic
contro- versy: Prevention and treatment of diabetes in children.
J Clin Endo- crinol Metab 2000;85:494–522.
 108. Binder C, Brange J. Insulin chemistry and pharmacokinetics.
In: Porte D Jr, Sherwin RS, eds. Ellenberg & Rifkin’s Diabetes
Mellitus, 5th ed. Stamford, CT: Appleton & Lange, 1997:689–
708.
BAGIAN 8
109. Kelly DB, ed. Management of Type 1 Diabetes Mellitus, 3rd
ed. Alexandria, VA: American Diabetes Association,
1998:211–222.
110. Halvorsen T, Levine F. Diabetes mellitus-cell transplantation
and gene therapy approaches. Curr Mol Med 2001;1:273–
286.
111. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation
in seven patients with type 1 diabetes mellitus using a
glucocorticoid-free immunosuppressive regimen. N Engl J
Med 2000;343:230–238.
Gangguan Endokrinologi
112. DeFronzo RA. Pharmacologic therapy for type 2 diabetes
mellitus. Ann Intern Med 1999;131:281–303.
113. Higa M, Zhou YT, Ravazzola M, et al. Troglitazone prevents
mito- chondrial alterations, beta cell destruction, and
diabetes in obese prediabetic rats. Proc Natl Acad Sci USA
1999;96:11513–11518.
114. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment
delays the onset of diabetes in 8 week-old db/db mice.
Diabetologia 2002:45;1263– 1273.
115. Shank ML, Del Prato S, DeFronzo RA. Bedtime
insulin/daytime glipizide. Effective therapy for sulfonylurea
failures in NIDDM. Diabe- tes 1995;44:165–172.
116. Yki-Jarvinen H, Ryysy L, Nikkila K. Comparison of bedtime
insulin regimens in patients with type 2 diabetes mellitus. A
randomized, controlled trial. Ann Intern Med 1999;130:389–
396.
117. Bastyr EJ, Stuart CA, Brodows RG. Therapy focused on
lowering postprandial glucose, not fasting glucose, may be
superior for lowering HbA1C. IOEZ Study Group. Diabetes
Care 2000;23:1236–1241.
118. European Diabetes Epidemiology Group. Glucose tolerance
and mortal- ity. Comparison of WHO and American Diabetes
Association diagnostic criteria. The DECODE study group.
Diabetes Epidemiology: Collabora- tive analysis of diagnostic
criteria in Europe. Lancet 1999;354:617–621.
119. Langer O, Conway DL, Berkus MD, et al. A comparison of
glyburide and insulin in women with gestational diabetes
mellitus. N Engl J Med 2000;343:1134–1138.
120. Laffel L. Sick-day management in type 1 diabetes.
Endocrinol Metab Clin North Am 2000;29:707–723.
121. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management
of hyper- glycemic crises in patients with diabetes. Diabetes
Care 2001;24:131–153.
122. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisburg RA.
Hyperglyce- mic crises in adult patients with diabetes. A
consensus statement from the American diabetes
association. Diabetes Care 2006;29:2739–2748.
123. Balasubramanyam A, Zern JW, Hyman DJ, Pavlik V. New
profiles of diabetic ketoacidosis: Type 1 vs. type 2 diabetes
and the effect of ethnicity. Arch Intern Med 1999;159:2317–
2322.
124. Glaser N, Barnett P, McCaslin I, et al. Pediatric Emergency
Medicine Collaborative Research Committee of the
American Academy of Pedi- atrics. N Engl J Med
2001;344:264–269.
125. Sawin CT. Action without benefit. The sliding scale of insulin
use. Arch Intern Med 1997;157:489.
126. Malmberg K, Norhammar A, Wedel H. Glycometabolic state at
admis- sion: Important risk marker of mortality in
conventionally treated patients with diabetes mellitus and
acute myocardial infarction: Long- term results from the
Diabetes and Insulin-Glucose Infusion in Acute Myocardial
Infarction (DIGAMI) Study. Circulation 1999;99:2626–2632.
127. van den Berghe G, Wouters P, Weekers F, et al. Intensive
insulin therapy in the critically ill patients. N Engl J Med
2001;345:1359–1367.
128. Montori VM, Bistrian BR, McMahon MM. Hyperglycemia in
acutely ill patients. JAMA 2002;288:2167–2169.
129. Clement S, Braithwaite SS, Magee MF, et al. Management
of diabetes and hyperglycemia in hospitals. Diabetes Care
2004;27:553–591.
130. Dumo P, Knapp E, Wesley G. Inappropriate metformin use
in hospi- talized patients [abstract 503-P], ADA 63rd Annual
Scientific Sessions, New Orleans, LA, 2002.
131. Jacober SJ, Sowers JR. An update on perioperative
management of diabetes. Arch Intern Med 1999;159:2405–
2411.
132. American Diabetes Association. Preconception care of
women with diabetes. Diabetes Care 2004;27(Suppl 1):S76–
S78.
133. Ryan EA. Pregnancy in diabetes. Med Clin North Am
1998;82:823– 845.
134. Buchbinder A, Miodovnik M, McElvy S, et al. Is insulin lispro
associated with the development or progression of diabetic
retinopathy during pregnancy? Am J Obstet Gynecol
2000;183:1162–1165.
135. Schernthaner G. Progress in the immunointervention of
type 1 diabe- tes mellitus. Horm Metab Res 1995;27:547–
554.
136. Diabetes Prevention Trial-Type 1 Diabetes Study Group.
Effects of insulin in relatives of patients with type 1 diabetes
mellitus. N Engl J Med 2002;346:1685–1691.
137. Kakka R, Koda-Kimble MA. Can insulin therapy delay or
prevent insulin- dependent diabetes mellitus?
Pharmacotherapy 1997;17:38–44.
138. Diabetes Prevention Program Research Group. Reduction
in the incidence of type 2 diabetes with lifestyle intervention
or metformin. N Engl J Med 2002;346:393–403.
139. Tuomilehto J, Lindstrom J, Eriksson JG, et al. for the Finnish
Diabetes Prevention Study Group. Prevention of type 2
diabetes mellitus by changes in lifestyle among subjects with
impaired glucose tolerance. N Engl J Med 2001;344:1343–
1350.
140. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of
pancreatic
-cell function and prevention of type 2 diabetes by
pharmacological treatment of insulin resistance in high-risk
Hispanic women. Diabetes 2002;51:2796–2803.
141. The DREAM Trial Investigators. The effect of ramipril on the
inci- dence of diabetes. N Engl J Med 2006;355:1551–1562.
142. The DREAM Trial Investigators. The effect of rosiglitazone
on the frequency of diabetes in patients with impaired
glucose tolerance or impaired fasting glucose. A randomised
controlled trial. Lancet 2006;368:1096–1105.
143. Nathan DM, Davidson MB, Defronzo RA, et al. Impaired
fasting glucose and impaired glucose tolerance. Implication
for care. Diabetes Care 2007;30:753–759.
144. Mensing C, Boucher J, Cypress M, et al. National standards
for diabetes self-management education. Diabetes Care
2000;23:682–689.
145. Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic
retinopathy. Diabetes Care 2004;27:2540–2553.
146. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic
somatic neuropathies. Diabetes Care 2004;27:1458–1486.
147. American Diabetes Association. Diabetic nephropathy.
Diabetes Care 2004;27(Suppl 1):S79–S83.
148. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective
effect of the angiotensin-receptor antagonist irbesartan in
patients with nephropa- thy due to type 2 diabetes. N Engl J
Med 2001;345:851–860.
149. Brenner BM, Cooper ME, deZeeuw D, et al. Effects of
losartan on renal and cardiovascular outcomes in patients
with type 2 diabetes and nephropathy. N Engl J Med
2001;345:861–869.
150. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The
effect of irbesartan on the development of diabetic
nephropathy in patients with type 2 diabetes. N Engl J Med
2001;345:870–878.
151. American Diabetes Association. Consensus development
conference on diabetic foot wound care, April 7–8, 1999
Boston, MA. Diabetes Care 1999;22:1354–1360.
152. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and
diabetes (techni- cal review). Diabetes Care 1999;22:1887–
1898.
153. American Diabetes Association. Aspirin therapy. Diabetes
Care 2004;27(Suppl 1):S72–S73.
154. Orchard TJ, Forrest KY, Kuller LH, Becker DJ. Lipid and blood
pressure treatment goals for type 1 diabetes: 10-Year
incidence data from the Pittsburgh Epidemiology of Diabetes
Complications Study. Diabetes Care 2001;24:1053–1059.
155. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary
prevention of cardiovascular disease with atorvastatin in
type 2 diabetes in the collaborative atorvastatin diabetes
study (CARDS): A multicentre, randomised placebo-
controlled trial. Lancet 2004;364:685–696.
156. Heart Protection Study Collaborative Group. MRC/BHF
Heart Protec- tion Study of cholesterol-lowering with
simvastatin in 5963 people with diabetes: A randomised
placebo-controlled trial. Lancet 2003;361:2005– 2016.
157. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the
secondary prevention of coronary heart disease in men with
low levels of high- density lipoprotein cholesterol. Veterans
Affairs High-Density Lipo- protein Cholesterol Intervention
Trial Study Group. N Engl J Med 1999;341:410–418.
158. The FIELD Study Investigators. Effects of long-term fenofibrate
therapy on cardiovascular events in 9795 people with type 2
diabetes mellitus (the FIELD study): Randomised controlled
trial. Lancet 2005;366:1849– 1861.
159. Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults. Executive summary of the
third report of the National Cholesterol Education Program
(NCEP) expert panel on detection, evaluation, and treatment
of high blood cholesterol in adults (Adult Treatment Panel III).
JAMA 2001;285:2486–2496.
160. Grundy SM, Cleeman JI, Merz CN. Implications of recent
163. Deedwania PC. Hypertension and diabetes: New
clinical trials for the national cholesterol education program
adult treatment panel III guidelines. Circulation therapeutic options. Arch Intern Med 2000;160:1585–1594.
2004;110:227–239. 164. Robertson RP, Davis C, Larsen J, et al. Pancreas and islet

161. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive
blood- pressure lowering and low-dose aspirin in patients
with hypertension: Principal results of the Hypertension
Optimal Treatment (HOT) randomised trial. HOT Study
Group. Lancet 1998;351:1755–1762.
162. Bakris GL, Williams M, Dworkin L, et al. Preserving renal
function in adults with hypertension and diabetes: A
consensus approach. National Kidney Foundation
Hypertension and Diabetes Executive Committees Working
BAB 77
transplanta- tion for patients with diabetes mellitus (technical
review). Diabetes Care 2000;23:112–116.
165. Herman WH, Eastman RC. The effects on treatment on the
direct costs of diabetes. Diabetes Care 1998;21(Suppl
3):C19-C24.
166. Gray A. Raikou M, McGuire A, et al. Cost effectiveness of an
intensive blood glucose control policy in patient with type 2
diabetes: Economic analysis alongside randomized
controlled trial (UKPDS 41). BMJ 2000;320:1373–1378.
167. Anonymous. Cost effectiveness analysis of improved blood

Diabetes Mellitus
Group. Am J Kidney Dis 2000;36:646–661.
pressure control in hypertensive patients with type 2
diabetes: UKPDS 40. BMJ 1998;317:720–726.
168. American Diabetes Association. Dyslipidemia management
in adults with diabetes. Diabetes Care 2004;27:S68–S71.